$0.90
+0.05 (+5.70%)
Open$0.85
Previous Close$0.85
Day High$0.92
Day Low$0.85
52W High$1.64
52W Low$0.77
Volume—
Avg Volume67.6K
Market Cap11.70M
P/E Ratio—
EPS$-4.58
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+2,243.3% upside
Current
$0.90
$0.90
Target
$21.09
$21.09
$14.27
$21.09 avg
$34.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 8.37M | 557.3K | 516.3K |
| Net Income | -501,680,813 | 76.7K | 85.4K |
| Profit Margin | -1,132.4% | 13.8% | 16.5% |
| EBITDA | -370,690,927 | 122.1K | 108.8K |
| Free Cash Flow | — | 55.8K | 59.0K |
| Rev Growth | +166.9% | +2.4% | +15.9% |
| Debt/Equity | 0.21 | 0.52 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |